Who
Marino Garcia
Director
Company insider
Files Form 4 as: Director, AgomAb Therapeutics NV; CEO and President, Dianthus Therapeutics; EVP and Chief Strategy Officer, Synergy Pharmaceuticals.
In numbers
- Trades disclosed
- 54
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $55.9M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 24 Jun 2016
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | AGMB AgomAb Therapeutics NVoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,482 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | AGMB AgomAb Therapeutics NVoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,482 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $338K40,000 at $8.44 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —126,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.1M126,000 at $8.44 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M10,384 at $107.49 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —40,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —126,000 at $0.00 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.6M23,907 at $108.05 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $259K2,373 at $109.10 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $279K2,536 at $110.02 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $89K800 at $110.76 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $11.2M104,091 at $107.96 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.4M21,909 at $108.72 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $338K40,000 at $8.44 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.1M126,000 at $8.44 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.1M10,384 at $107.49 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.6M23,907 at $108.05 | filing |
| 7 Aug 2026filed 7 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $259K2,373 at $109.10 | filing |
News
Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaDNTH · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Marino Garcia; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.